The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: A multinational, double‐blind, randomized, placebo‐controlled clinical trial
Abstract
Objective: Current treatment options for psoriatic arthritis (PsA) are limited. Leflunomide, an oral pyrimidine synthesis inhibitor, is highly effective in the treatment of rheumatoid arthritis, and small studies have suggested similar efficacy in PsA. We undertook this double‐blind, randomized, placebo‐controlled trial to evaluate the efficacy and safety of leflunomide in patients with PsA and psoriasis. Methods: One hundred ninety patients with active PsA and psoriasis (at least 3% skin involvement) were randomized to receive leflunomide (100 mg/day loading dose for 3 days followed by 20 mg/day orally) or placebo for 24 weeks. The primary efficacy end point was the proportion of patients classified as responders by the Psoriatic Arthritis Response Criteria (PsARC). Additional efficacy (joint and skin involvement), safety, and quality‐of‐life assessments were performed. Results: At 24 weeks, 56 of 95 leflunomide‐treated patients (58.9%; 95% confidence interval [95% CI] 48.4–68.9) and 27 of 91 placebo‐treated patients (29.7% [95% CI 20.6–40.2]) were classified as responders by the PsARC (P < 0.0001). Significant differences in favor of leflunomide were also observed in the proportions of patients achieving modified American College of Rheumatology 20% improvement criteria, improvement in the designated psoriasis target lesion, and mean changes from baseline in Psoriasis Area and Severity Index scores and quality‐of‐life assessments. Diarrhea and alanine aminotransferase increases occurred at higher rates in the leflunomide group. No cases of serious liver toxicity were observed. Conclusion: Leflunomide is an effective treatment for PsA and psoriasis, providing a safe and convenient alternative to current therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical use
FINLAY, A. Y., & KHAN, G. K. (1994) · Clinical and Experimental Dermatology · doi:10.1111/j.1365-2230.1994.tb01167.x · Cited by 5,586
American college of rheumatology preliminary definition of improvement in rheumatoid arthritis
Felson, D. T., Anderson, J. J., Boers, M., Bombardier, C., Furst, D., Goldsmith, C., Katz, L. M., Lightfoot, R., Paulus, H., Strand, V., et al. (1995) · Arthritis & Rheumatism · doi:10.1002/art.1780380602 · Cited by 2,829
Severe Psoriasis – Oral Therapy with a New Retinoid
Fredriksson, T., & Pettersson, U. (2009) · Dermatologica · doi:10.1159/000250839 · Cited by 2,718
Felson, D. T., Anderson, J. J., Boers, M., Bombardier, C., Chernoff, M., Fried, B., Furst, D., Goldsmith, C., Kieszak, S., Lightfoot, R., et al. (1993) · Arthritis & Rheumatism · doi:10.1002/art.1780360601 · Cited by 1,640
Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial
Mease, P. J., Goffe, B. S., Metz, J., VanderStoep, A., Finck, B., & Burge, D. J. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02530-7 · Cited by 1,446
Self-citationSmolen, J. S., Kalden, J. R., Scott, D. L., Rozman, B., Kvien, T. K., Larsen, A., Loew-Friedrich, I., Oed, C., & Rosenburg, R. (1999) · The Lancet · doi:10.1016/s0140-6736(98)09403-3 · Cited by 771
Treatment of Active Rheumatoid Arthritis With Leflunomide Compared With Placebo and Methotrexate
Strand, V. (1999) · Archives of Internal Medicine · doi:10.1001/archinte.159.21.2542 · Cited by 754
KIRWAN, J. R., & REEBACK, J. S. (1986) · Rheumatology · doi:10.1093/rheumatology/25.2.206 · Cited by 488
Leflunomide: mode of action in the treatment of rheumatoid arthritis
Breedveld, F. C., & Dayer, J.-M. (2000) · Annals of the Rheumatic Diseases · doi:10.1136/ard.59.11.841 · Cited by 485
Emery, P., Breedveld, F. C., Lemmel, E. M., Kaltwasser, J. P., Dawes, P. T., Gömör, B., Van den Bosch, F., Nordström, D., Bjørneboe, O., Dahl, R., et al. (2000) · Rheumatology · doi:10.1093/rheumatology/39.6.655 · Cited by 472
Self-citation(1993) · PubMed · Cited by 469
Clegg, D. O., Reda, D. J., Mejias, E., Cannon, G. W., Weisman, M. H., Taylor, T., Budiman‐Mak, E., Blackburn, W. D., Vasey, F. B., Mahowald, M. L., et al. (1996) · Arthritis & Rheumatism · doi:10.1002/art.1780391210 · Cited by 447
The epidemiology of psoriatic arthritis in Olmsted County, Minnesota, USA, 1982-1991.
Shbeeb, M. I., Uramoto, K. M., Gibson, L. E., O’Fallon, W. M., & Gabriel, S. E. (2000) · PubMed · Cited by 392
Risk of Malignancies in Psoriasis Patients Treated with Cyclosporine: a 5 y Cohort Study
Paul, C. F., HO, V. C., McGeown, C., et al. (2003) · Journal of Investigative Dermatology · doi:10.1046/j.1523-1747.2003.12040.x · Cited by 388
Methotrexate and histologic hepatic abnormalities: A meta-analysis
Whiting-O'Keefe, Q. E., Fye, K. H., & Sack, K. D. (1991) · The American Journal of Medicine · doi:10.1016/s0002-9343(05)80060-9 · Cited by 358
Husted, J. A., Gladman, D. D., Farewell, V. T., & Cook, R. J. (2001) · Arthritis & Rheumatism · doi:10.1002/1529-0131(200104)45:2<151::aid-anr168>3.0.co;2-t · Cited by 347
Self-citationWong, K., Gladman, D. D., Husted, J., Long, J. A., Farewell, V. T., & Long, J. A. (1997) · Arthritis & Rheumatism · doi:10.1002/art.1780401021 · Cited by 339
Self-citationMethotrexate Therapy in Psoriatic Arthritis: Double-Blind Study on 21 Patients
Black, R. L., O'Brien, W. M., Van Scott, E. J., Auerbach, R., Eisen, A. Z., & Bunim, J. J. (1964) · JAMA · doi:10.1001/jama.1964.03070100037007 · Cited by 307
Injection of Pre-Psoriatic Skin with CD4+ T Cells Induces Psoriasis
Nickoloff, B. J., & Wrone-Smith, T. (1999) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65109-7 · Cited by 260
A systematic review of treatments for severe psoriasis.
Griffiths, Clark, Chalmers, Po, L. W., & Williams (2000) · Health Technology Assessment · doi:10.3310/hta4400 · Cited by 232
Cytokine production by synovial T cells in rheumatoid arthritis
Steiner, G. (1999) · Rheumatology · doi:10.1093/rheumatology/38.3.202 · Cited by 228
Assessing the clinical importance of symptomatic improvements. An illustration in rheumatology
Redelmeier, D. A. (1993) · Archives of Internal Medicine · doi:10.1001/archinte.153.11.1337 · Cited by 181
Antoni, C., Dechant, C., Hanns‐Martin Lorenz, P. D., Wendler, J., Ogilvie, A., Lueftl, M., Kalden‐Nemeth, D., Kalden, J. R., & Manger, B. (2002) · Arthritis Care & Research · doi:10.1002/art.10671 · Cited by 177
Badia, Mascaró, Lozano, & ON BEHALF OF THE CAVIDE RESEARCH GROUP (1999) · British Journal of Dermatology · doi:10.1046/j.1365-2133.1999.03112.x · Cited by 170
Kraan, M. C., van Kuijk, A. W. R., Dinant, H. J., Goedkoop, A. Y., Smeets, T. J. M., de Rie, M. A., Dijkmans, B. A. C., Vaishnaw, A. K., Bos, J. D., & Tak, P. P. (2002) · Arthritis & Rheumatism · doi:10.1002/art.10543 · Cited by 150
Costello, P. J., WINCHESTER, R. J., Curran, S. A., et al. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.4.2878 · Cited by 124
Tassiulas, I. O., Duncan, S. R., Centola, M. B., Theofilopoulos, A. N., & Boumpas, D. T. (1999) · Human Immunology · doi:10.1016/s0198-8859(99)00034-8 · Cited by 101
Open Trial of Leflunomide for Refractory Psoriasis and Psoriatic Arthritis
Liang, G. C., & Barr, W. G. (2001) · JCR Journal of Clinical Rheumatology · doi:10.1097/00124743-200112000-00003 · Cited by 36
Cited by
Braun, J., & Sieper, J. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60635-7 · Cited by 1,806
Psoriatic arthritis: epidemiology, clinical features, course, and outcome
Gladman, D. D., Antoni, C., Mease, P., Clegg, D. O., & Nash, P. (2005) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2004.032482 · Cited by 1,536
Self-citationRitchlin, C. T., Colbert, R. A., & Gladman, D. D. (2017) · New England Journal of Medicine · doi:10.1056/nejmra1505557 · Cited by 1,404
Self-citationMease, P. J., Gladman, D. D., Ritchlin, C. T., Ruderman, E. M., Steinfeld, S. D., Choy, E. H. S., Sharp, J. T., Ory, P. A., Perdok, R. J., & Weinberg, M. A. (2005) · Arthritis & Rheumatism · doi:10.1002/art.21306 · Cited by 909
Self-citationBasra, M. K. A., Fenech, R., Gatt, R. M., Salek, M. S., & Finlay, A. Y. (2008) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2008.08832.x · Cited by 789
Metadata
- Authors
- Kaltwasser, J. P., Nash, P., Gladman, D., Rosen, C. F., Behrens, F., Jones, P., Wollenhaupt, J., Falk, F. G., & Mease, P.
- Venue
- Arthritis & Rheumatism
- Publisher
- Wiley
- Published
- 2004-06
- Volume
- 50
- Issue
- 6
- Pages
- 1939-1950
- ISSN
- 0004-3591 (ISSN-L)
- 1529-0131
- OpenAlex
- W1968958817
- Cited by
- 413
- References
- 28
- FWCI
- 19.86
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.